Sigma Planning Corp boosted its position in Johnson & Johnson (NYSE:JNJ) by 10.8% during the 3rd quarter, Holdings Channel.com reports. The firm owned 101,643 shares of the company’s stock after purchasing an additional 9,921 shares during the period. Johnson & Johnson comprises about 0.6% of Sigma Planning Corp’s portfolio, making the stock its 24th biggest holding. Sigma Planning Corp’s holdings in Johnson & Johnson were worth $13,151,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of JNJ. Cypress Capital Management LLC raised its holdings in Johnson & Johnson by 3.5% during the 3rd quarter. Cypress Capital Management LLC now owns 37,568 shares of the company’s stock valued at $4,861,000 after acquiring an additional 1,257 shares during the period. Inscription Capital LLC raised its holdings in Johnson & Johnson by 307.4% during the 3rd quarter. Inscription Capital LLC now owns 13,005 shares of the company’s stock valued at $1,683,000 after acquiring an additional 9,813 shares during the period. Alley Co LLC raised its holdings in Johnson & Johnson by 10.9% during the 3rd quarter. Alley Co LLC now owns 6,134 shares of the company’s stock valued at $794,000 after acquiring an additional 604 shares during the period. Stelac Advisory Services LLC bought a new stake in Johnson & Johnson during the 3rd quarter valued at $295,000. Finally, Sageworth Trust Co raised its holdings in Johnson & Johnson by 3.5% during the 3rd quarter. Sageworth Trust Co now owns 4,452 shares of the company’s stock valued at $576,000 after acquiring an additional 150 shares during the period. Institutional investors and hedge funds own 72.25% of the company’s stock.
A number of equities research analysts have issued reports on JNJ shares. Bank of America reissued a “hold” rating and set a $150.00 target price on shares of Johnson & Johnson in a report on Tuesday, July 16th. Goldman Sachs Group set a $169.00 target price on shares of Johnson & Johnson and gave the company a “buy” rating in a report on Tuesday, August 27th. Atlantic Securities raised shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a report on Wednesday, October 16th. Morgan Stanley reissued an “equal weight” rating and set a $145.00 target price on shares of Johnson & Johnson in a report on Tuesday, August 27th. Finally, Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, July 16th. Six research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $151.64.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share for the quarter, topping the consensus estimate of $2.00 by $0.12. The firm had revenue of $20.73 billion for the quarter, compared to analysts’ expectations of $20.14 billion. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.81%. The business’s quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.05 earnings per share. As a group, equities analysts expect that Johnson & Johnson will post 8.65 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be issued a $0.95 dividend. The ex-dividend date is Monday, November 25th. This represents a $3.80 annualized dividend and a dividend yield of 2.86%. Johnson & Johnson’s payout ratio is currently 46.45%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: How to find the components of the quick ratio
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.